Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Baba Website

Masaya Baba, M.D., Ph.D.

Selected Publications
1)  Hasumi H, Baba M, Hasumi Y, Huang Y, Oh HF, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM.
Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN.
J Natl Cancer Inst. in press, 2012. [Journal]
2)  Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon KR, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, Casellas R.
The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development.
Blood. 120: 1254-61, 2012. [Journal]
3)  Benhammou JN, Vocke CD, Santani A, Schmidt LS, Baba M, Seyama K, Wu X, Korolevich S, Nathanson KL, Stolle CA, Linehan WM.
Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dube syndrome.
Genes Chromosomes Cancer. 50: 466-77, 2011. [Journal]
4)  Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM.
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
PLoS ONE. 5: e15793, 2010. [Journal]
5)  Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.
Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
Mol. Cancer. 9: 160, 2010. [Journal]
6)  Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM.
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
Proc. Natl. Acad. Sci. U.S.A. 106: 18722-7, 2009. [Journal]
7)  Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Sano F, Baba M, Kondo K, Nakaigawa N, Kishida T, Nagashima Y, Yamada-Okabe H, Kubota Y.
A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma.
Int. J. Cancer. 123: 1126-32, 2008. [Journal]
8)  Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS.
Identification and characterization of a novel folliculin-interacting protein FNIP2.
Gene. 415: 60-7, 2008. [Journal]
9)  Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
J. Natl. Cancer Inst. 100: 140-54, 2008. [Journal]
10)  Hattori K, Teranishi J, Stolle C, Yoshida M, Kondo K, Kishida T, Kanno H, Baba M, Kubota Y, Yao M.
Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease.
Cancer Sci. 97: 400-5, 2006. [Journal]
11)  Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR, Linehan WM, Schmidt LS, Zbar B.
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
Proc. Natl. Acad. Sci. U.S.A. 103: 15552-7, 2006. [Journal]
12)  Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y.
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.
Cancer Res. 66: 3699-705, 2006. [Journal]
13)  Hong SB, Furihata M, Baba M, Zbar B, Schmidt LS.
Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis.
Lab. Invest. 86: 664-75, 2006. [Journal]
14)  Kato Y, Lambert CA, Colige AC, Mineur P, Noël A, Frankenne F, Foidart JM, Baba M, Hata R, Miyazaki K, Tsukuda M.
Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling.
J. Biol. Chem. 280: 10938-44, 2005. [Journal]
15)  Yao M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, Ishiguro H, Hamada K, Inayama Y, Kishida T, Hattori K, Yamada-Okabe H, Kubota Y.
Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.
J. Pathol. 205: 377-87, 2005. [Journal]
16)  Ma W, Tessarollo L, Hong SB, Baba M, Southon E, Back TC, Spence S, Lobe CG, Sharma N, Maher GW, Pack S, Vortmeyer AO, Guo C, Zbar B, Schmidt LS.
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
Cancer Res. 63: 5320-8, 2003. [Journal]
17)  Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S.
Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Oncogene. 22: 2728-38, 2003. [Journal]
18)  Yamada H, Dezawa M, Shimazu S, Baba M, Sawada H, Kuroiwa Y, Yamamoto I, Kanno H.
Transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson"s disease.
Ann. Neurol. 54: 352-9, 2003. [Journal]
19)  Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, Kawakami S, Baba M, Nakaigawa N, Nagashima Y, Nakatani Y, Hosaka M.
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
Genes Chromosomes Cancer. 34: 58-68, 2002. [Journal]
20)  Hirai S, Kawaguchi A, Hirasawa R, Baba M, Ohnishi T, Ohno S.
MAPK-upstream protein kinase (MUK) regulates the radial migration of immature neurons in telencephalon of mouse embryo.
Development. 129: 4483-95, 2002. [Journal]
21)  Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, Miura T, Moriyama M, Nagashima Y, Nakatani Y, Kubota Y, Kondo K.
VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma.
J. Natl. Cancer Inst. 94: 1569-75, 2002. [Journal]
22)  Murata H, Tajima N, Nagashima Y, Yao M, Baba M, Goto M, Kawamoto S, Yamamoto I, Okuda K, Kanno H.
Von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells.
Cancer Res. 62: 7004-11, 2002. [Journal]
23)  Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, Minato N, Ohno S, Shuin T.
The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.
J. Biol. Chem. 276: 43611-7, 2001. [Journal]
24)  Baba M, Hirai S, Kawakami S, Kishida T, Sakai N, Kaneko S, Yao M, Shuin T, Kubota Y, Hosaka M, Ohno S.
Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth.
Oncogene. 20: 2727-36, 2001. [Journal]
25)  Yoshida M, Ashida S, Kondo K, Kobayashi K, Kanno H, Shinohara N, Shitara N, Kishida T, Kawakami S, Baba M, Yamamoto I, Hosaka M, Shuin T, Yao M.
Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families.
Jpn. J. Cancer Res. 91: 204-12, 2000. [Journal]
26)  Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, Kishida T, Kaneko S, Yao M, Ohno S, Shuin T.
Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes.
Biochem. Biophys. Res. Commun. 263: 491-7, 1999. [Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 9/8/2012.